Shionogi Gets Untitled Letter After Refusing To Conduct Postmarketing Study

Drug Industry Daily
A A
The FDA issued Shionogi an untitled letter for refusing to conduct a postmarketing study required as part of an NDA approval.

To View This Article:

Login

Subscribe To Drug Industry Daily